Skip to main content

Table 1 Prevalence of antibodies to full-length Ro52 and Ro52 epitopes and peptides in patients with SARDs and controls

From: Serological epitope profile of anti-Ro52–positive patients with systemic autoimmune rheumatic diseases

  Ro52 epitopes   Ro52 peptides
  1 2 3 4 5 Full-length Ro52 200–239 aa 175–196 aa
Total SARDs (n = 100) 3 (3 %) 97 (97 %) 0 9 (9 %) 28 (28 %) 100 (100 %) 74 (74 %) 6 (6 %)
MCTD (n = 7) 0 7 (100 %) 0 0 2 (29 %) 7 (100 %) 5 (71 %) 0
Myositis (n = 27) 1 (4 %) 24 (89 %) 0 3 (11 %) 5 (19 %) 27 (100 %) 16 (59 %) 1 (4 %)
RA (n = 7) 0 7 (100 %) 0 0 2 (29 %) 7 (100 %) 5 (71 %) 0
SLE (n = 23) 1 (4 %) 23 (100 %) 0 1 (4 %) 6 (26 %) 23 (100 %) 19 (83 %) 2 (8 %)
SjS (n = 34) 1 (3 %) 34 (100 %) 0 5 (15 %) 13 (38 %) 34 (100 %) 28 (82 %) 3 (9 %)
SSc (n = 2) 0 2 (100 %) 0 0 0 2 (100 %) 1 (50 %) 0
Controls (n = 68) 0 0 0 0 0 0 1 (1 %) 1 (1 %)
  1. MCTD Mixed connective tissue disease, SLE systemic lupus erythematosus, RA rheumatoid arthritis, SSc systemic sclerosis, SjS Sjögren’s syndrome, aa amino acid, SARD systemic autoimmune rheumatic disease
  2. Data are presented as number (%)
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us